Shanghai Haiyan Medical Technology

Shanghai Haiyan Pharmaceutical Technology specializes in developing first-in-class small-molecule therapeutics primarily targeting oncology and acute pain indications. As a wholly-owned subsidiary of Yangtze River Pharmaceutical Group since its founding in May 2011 at Zhangjiang Pharma Valley (Shanghai), it has advanced several candidates into mid-stage clinical development—including Mat2A inhibitors for cancer therapy—and maintains strong hospital-based research partnerships throughout China. The company's current lead programs are progressing through late-stage clinical trials but no marketed products or public financial data have been disclosed as of mid–2025.